Jim Wassil - Feb 27, 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
CHIEF OPERATING OFFICER
Signature
Jim Wassil, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Feb 27, 2025
Transactions value $
-$658,216
Form type
4
Date filed
3/3/2025, 09:14 PM
Previous filing
Feb 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Award $0 +21.7K +16.5% $0.00 153K Feb 27, 2025 Direct F1
transaction PCVX Common Stock Award $412K +5.65K +3.68% $73.02 159K Feb 28, 2025 Direct F2
transaction PCVX Common Stock Tax liability -$209K -2.87K -1.8% $73.02 156K Feb 28, 2025 Direct F3
transaction PCVX Common Stock Tax liability -$92.7K -1.27K -0.81% $73.02 155K Feb 28, 2025 Direct F3
transaction PCVX Common Stock Options Exercise $6.38K +2.64K +1.7% $2.42 158K Mar 3, 2025 Direct
transaction PCVX Common Stock Options Exercise $28.7K +5.36K +3.4% $5.35 163K Mar 3, 2025 Direct
transaction PCVX Common Stock Sale -$432K -5.92K -3.63% $73.07 157K Mar 3, 2025 Direct F4, F5
transaction PCVX Common Stock Sale -$154K -2.09K -1.33% $73.84 155K Mar 3, 2025 Direct F4, F6
transaction PCVX Common Stock Tax liability -$217K -3.02K -1.95% $72.10 152K Mar 3, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Award $0 +72.5K $0.00 72.5K Feb 27, 2025 Common Stock 72.5K $74.22 Direct F7
transaction PCVX Stock Option (right to buy) Options Exercise $0 -2.64K -100% $0.00 0 Mar 3, 2025 Common Stock 2.64K $2.42 Direct F8
transaction PCVX Stock Option (right to buy) Options Exercise $0 -5.36K -6.96% $0.00 71.7K Mar 3, 2025 Common Stock 5.36K $5.35 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2 Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant.
F3 Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F4 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.
F5 The price reported is a weighted-average price. The shares were sold at prices ranging from $72.50 to $73.47. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6 The price reported is a weighted-average price. The shares were sold at prices ranging from $73.51 to $74.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F8 Option is fully vested and exercisable.